Trestolone is a synthetic androgen that inhibits the release of follicle-stimulating hormone and impairs spermatogenesis. Luteinizing hormone is also suppressed, which cuts production of testosterone. The azoospermia and oligospermia are reversible after discontinuation of trestolone. Trestolone has androgenic and anabolic properties and loss of secondary sex characteristics is not seen. Like testosterone, trestolone undergoes enzymatic aromatization to an estrogen. The use of trestolone instead of testosterone for androgen replacement therapy could have health-promoting effects by reducing the occurrence of prostate disease. Trestolone had been in phase II clinical trial for the andropause control. However, this development was discontinued.

Fluorescein Lisicol (NRL972) is a fluorescent-labelled bile acid analog that is used as an investigational marker for liver function, specifically hepatic biliary transporter function. Fluorescein Lisicol has been used in trials investigating the pharmacokinetics of hepatic cirrhosis, viral hepatitis, non-alcoholic steatohepatitis and non-alcoholic fatty liver disease.

NeuroSearch was developing brasofensine (or NS 2214), an oral dopamine reuptake inhibitor for the treatment of Parkinson's disease. Brasofensine successfully passed phase II clinical trial in patients with Parkinson's disease, The drug was safe and well tolerated. However, NeuroSearch discontinued the development of the drug because of the cis-anti isomerization of the 2α-methyloxime group of brasofensine in favor of NS 2230.

Propetandrol is a pregnanediol derivative patented by Schering A.-G. as long-acting anabolic androgen. Propetandrol is potent in the prevention of tissue calcification and skeletal lesions.

Etersalate is a derivative of aspirin exerting antiplatelet, analgesic, anti-inflammatory and antipyretic properties. Etersalate has potential to prevent oligomerization of amyloid beta (Aβ) peptides.

Meseclazone (W-2395) is a non-steroidal anti-inflammatory drug. It exerts anti-inflammatory, analgesic and antipyretic activity. Meseclazone inhibits in vitro and ex vivo platelet aggregation initiated by the release reaction. It inhibits bradykinin-induced bronchospasm.

Clostebol is a synthetic anabolic-androgenic steroid, a derivative of the natural hormone testosterone. Clostebol is a Schedule III controlled substance used medically in topical ophthalmologic and dermatologic treatments. Due to potential use as a performance-enhancing drug, clostebol is banned by the World Anti-Doping Agency.

Democonazole is the antimycotic agent.

Deloxolone was devoid of aldosterone-like properties. Deloxolone could be of therapeutic value in peptic ulcer diseases without inducing fluid retention, hypertension and hypokaliemia. Carbenoxolone and deloxolone were orally administered to healthy volunteers in a cross-over double-blind trial. Both the concentration in gastric juice and the output of PGE2, determined by an RIA method in basal conditions and after pentagastrin bolus, increased in drug-treated compared to vehicle-treated subjects thus supporting the hypothesis that cytoprotection might be due to gastric PGE, levels. Moreover, deloxolone induced less marked effects than carbenoxolone on body weight, hematocrit, plasma potassium and proteins, confirming that deloxolone is less similar to aldosterone than the reference drug.

Levopropylcillin – is a penicillin derivative, L-enantiomer of antibiotic Propicillin. Levopropylcillin properties are similar to benzylpenicillin particularly used in streptococcal infections, not resistant to penicillinase. Levopropylcillin is acid resistant and can be used orally as the potassium salt.